Aristeia Capital L.L.C. Invests $444,000 in IQVIA Holdings Inc. $IQV

Aristeia Capital L.L.C. bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the first quarter, HoldingsChannel.com reports. The firm bought 2,518 shares of the medical research company’s stock, valued at approximately $444,000.

A number of other institutional investors have also recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd acquired a new position in IQVIA in the 1st quarter worth about $1,351,000. UniSuper Management Pty Ltd boosted its position in shares of IQVIA by 3.1% during the 1st quarter. UniSuper Management Pty Ltd now owns 16,654 shares of the medical research company’s stock valued at $2,936,000 after purchasing an additional 500 shares in the last quarter. Punch & Associates Investment Management Inc. increased its holdings in IQVIA by 16.6% in the first quarter. Punch & Associates Investment Management Inc. now owns 68,765 shares of the medical research company’s stock worth $12,123,000 after purchasing an additional 9,791 shares in the last quarter. Petrus Trust Company LTA increased its holdings in IQVIA by 151.1% in the first quarter. Petrus Trust Company LTA now owns 3,071 shares of the medical research company’s stock worth $541,000 after purchasing an additional 1,848 shares in the last quarter. Finally, Nissay Asset Management Corp Japan ADV increased its holdings in IQVIA by 0.8% in the first quarter. Nissay Asset Management Corp Japan ADV now owns 22,428 shares of the medical research company’s stock worth $3,954,000 after purchasing an additional 181 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

IQV has been the topic of several recent research reports. Barclays increased their price target on IQVIA from $165.00 to $185.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 23rd. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Cowen reissued a “buy” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Citigroup reissued a “neutral” rating on shares of IQVIA in a research report on Thursday, May 22nd. Finally, Robert W. Baird boosted their price target on shares of IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $229.86.

Insider Activity at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

IQVIA Price Performance

IQV opened at $187.75 on Monday. The stock’s 50 day simple moving average is $179.88 and its 200 day simple moving average is $167.23. The firm has a market cap of $31.92 billion, a price-to-earnings ratio of 27.17, a PEG ratio of 2.06 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $249.43.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.IQVIA’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.